Twist Bioscience Corporation

Welcome to the Twist Biosciences fiscal 2022 third quarter financial results conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star one one on your telephone. Please be advised that today's conference is being recorded. I would now like to turn the conference call over to Angela Biden, SVP of Corporate Affairs and Chief ESG Officer.

Thank you, Operator. Good morning, everyone.

I'd like to thank all of you for joining us today for TWIS Biosciences' conference call to review our fiscal 2022 third quarter financial results and business progress. We issued our financial results release this morning, which is available at our website at www.twisbioscience.com. With me on today's call are Dr. Emily Leprous, CEO and co-founder of TWiST, and Jim Thorburn, CFO of TWiST. Emily will begin with a review of our recent progress on TWiST businesses. Jim will report on financial and operational performance. Emily will come back to discuss our upcoming milestones and directions. We will then open the call for questions. We ask that you limit your questions to a maximum of two and then re-queue as a courtesy to others on the call. As a reminder, this call is being recorded. The audio portion will be archived in the investor section of our website and will be available for two weeks. During today's presentation, we will make forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements generally relate to future events or future financial or operating performance. Our expectations and beliefs regarding these matters may not materialize, and actual results in financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in our press release we issued earlier today, as well as those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on information available to us as of the date hereof, and we cannot at this time predict the full extent of the ongoing impact of the COVID-19 pandemic and any resulting business or economic impact. We disclaim any obligation to update any forward-looking statements except as required by law. With that, I will now turn the call over to our chief executive officer and co-founder, Dr. Emily Leproust.